Development of drug carrier responding to Matrix Metalloproteinase II

Kentaro Nishi; Takeshi Mori; Takuro Niidome; Yoshiki Katayama

Development of drug carrier responding to Matrix Metalloproteinase II

Kentaro Nishi, Takeshi Mori, Takuro Niidome, Yoshiki Katayama

Research output: Contribution to conference › Paper › peer-review

Abstract

Matrix Metalloproteinase II (MMP II) plays a key role when cancer cells perform invasion and metastasis by degrading a collagen. Moreover, the expression of this proteinase is enhanced in bone destruction in rheumatoid arthritis. We create a novel drug delivery system that can respond to MMP II. In our DDS, the micelle which is formed from amphiphilic copolymers is used as a drug carrier. The copolymer is composed of hydrophobic polymer main chain and hydrophilic polyethylene glycol side chain which is linked to the main chain with substrate of MMP II. The micelle will be coagulated by digestion of the substrate by MMP II that is enhanced in cancer invasion and rheumatoid and will release the incorporated drug. To realize the DDS, we synthesized the copolymers and studied their physicochemical properties.

Original language	English
Number of pages	1
Publication status	Published - Oct 19 2006
Event	55th SPSJ Annual Meeting - Nagoya, Japan Duration: May 24 2006 → May 26 2006

Other

Other	55th SPSJ Annual Meeting
Country/Territory	Japan
City	Nagoya
Period	5/24/06 → 5/26/06

All Science Journal Classification (ASJC) codes

Engineering(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@conference{799edbf3622f4bc884cc992ddfcffb8f,

title = "Development of drug carrier responding to Matrix Metalloproteinase II",

abstract = "Matrix Metalloproteinase II (MMP II) plays a key role when cancer cells perform invasion and metastasis by degrading a collagen. Moreover, the expression of this proteinase is enhanced in bone destruction in rheumatoid arthritis. We create a novel drug delivery system that can respond to MMP II. In our DDS, the micelle which is formed from amphiphilic copolymers is used as a drug carrier. The copolymer is composed of hydrophobic polymer main chain and hydrophilic polyethylene glycol side chain which is linked to the main chain with substrate of MMP II. The micelle will be coagulated by digestion of the substrate by MMP II that is enhanced in cancer invasion and rheumatoid and will release the incorporated drug. To realize the DDS, we synthesized the copolymers and studied their physicochemical properties.",

author = "Kentaro Nishi and Takeshi Mori and Takuro Niidome and Yoshiki Katayama",

year = "2006",

month = oct,

day = "19",

language = "English",

note = "55th SPSJ Annual Meeting ; Conference date: 24-05-2006 Through 26-05-2006",

}

TY - CONF

T1 - Development of drug carrier responding to Matrix Metalloproteinase II

AU - Nishi, Kentaro

AU - Mori, Takeshi

AU - Niidome, Takuro

AU - Katayama, Yoshiki

PY - 2006/10/19

Y1 - 2006/10/19

N2 - Matrix Metalloproteinase II (MMP II) plays a key role when cancer cells perform invasion and metastasis by degrading a collagen. Moreover, the expression of this proteinase is enhanced in bone destruction in rheumatoid arthritis. We create a novel drug delivery system that can respond to MMP II. In our DDS, the micelle which is formed from amphiphilic copolymers is used as a drug carrier. The copolymer is composed of hydrophobic polymer main chain and hydrophilic polyethylene glycol side chain which is linked to the main chain with substrate of MMP II. The micelle will be coagulated by digestion of the substrate by MMP II that is enhanced in cancer invasion and rheumatoid and will release the incorporated drug. To realize the DDS, we synthesized the copolymers and studied their physicochemical properties.

AB - Matrix Metalloproteinase II (MMP II) plays a key role when cancer cells perform invasion and metastasis by degrading a collagen. Moreover, the expression of this proteinase is enhanced in bone destruction in rheumatoid arthritis. We create a novel drug delivery system that can respond to MMP II. In our DDS, the micelle which is formed from amphiphilic copolymers is used as a drug carrier. The copolymer is composed of hydrophobic polymer main chain and hydrophilic polyethylene glycol side chain which is linked to the main chain with substrate of MMP II. The micelle will be coagulated by digestion of the substrate by MMP II that is enhanced in cancer invasion and rheumatoid and will release the incorporated drug. To realize the DDS, we synthesized the copolymers and studied their physicochemical properties.

UR - http://www.scopus.com/inward/record.url?scp=33749818276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749818276&partnerID=8YFLogxK

M3 - Paper

AN - SCOPUS:33749818276

T2 - 55th SPSJ Annual Meeting

Y2 - 24 May 2006 through 26 May 2006

ER -

Development of drug carrier responding to Matrix Metalloproteinase II

Abstract

Other

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this